Neuralink, a pioneering company in brain-computer interface (BCI, originally), is moving forward with its goal of directly connecting the human brain to technology. The company announced the launch of a new feasibility test to test the use of the N1, a chip capable of controlling robotic arms.
Neuralink is focused on transforming lives
The company shared on social media:
We are pleased to announce the approval and launch of a new feasibility trial to extend BCI control using the N1 implant to an experimental robotic assist arm.
The study CONVOY is designed to benefit people with significantly limited mobility, such as quadriplegics, who have lost control of their limbs. Neuralink described this initiative as an essential step towards restoring both "digital and physical freedom".
Previously, the company had already demonstrated the potential of the N1 chip, when the first human test participant, Noland Arbaugh, used the implant to control a mouse cursor on the computer. The device works by interpreting brain signals and convert them into commands transmitted over Bluetooth to external devices.
We’re excited to announce the approval and launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm.
This is an important first step towards restoring not only digital freedom, but also physical freedom. More info…
— Neuralink (@neuralink) November 25, 2024
In August, Neuralink revealed that it successfully implanted the N1 chip in a second human patient. The company highlighted plans to expand the chip's capabilities, allowing users to interact with the physical world. This includes controlling robotic arms, operating wheelchairs and even carrying out tasks such as eating independently.
Although many details about the study, including the location where it will be carried out, have not yet been revealed, Neuralink has confirmed that participants in the PRIME study – which investigates the use of the N1 chip for digital applications – may also be part of the CONVOY study.
Recently, Neuralink expanded the PRIME study from the United States to Canada, thus expanding the potential number of participants for future advancements.
Also read:
Source: pplware.sapo.pt
